ESC 365 - Effect of sacubitril/valsartan therapy on risk stratification biomarkers in a real-world heart failure population

HFA Premium Access

Effect of sacubitril/valsartan therapy on risk stratification biomarkers in a real-world heart failure population

Session: Poster Session 4 - Biomarkers

Topic: Natriuretic peptides

Speaker: Doctor M. Barrett (Dublin, IE)

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Doctor Matthew Barrett

University College Dublin, Dublin (Ireland)

0 follower

13 more presentations in this session

NT-proBNP correlates with LAVi and LVMMi in patients with beta-thalassemia major

Speaker: Doctor M. Dimova-Mileva (Varna, BG)

Assessment nt-probnp in patients with chronic systolic heart failure depending of the quality of life

Speaker: Professor V. Maslovskyi (Vinnytsa, UA)

B-type natriuretic peptide and stage B heart failure in the prediction of cardiovascular events and death in hypertension.

Speaker: Doctor C. Watson (Belfast, GB)

Features of correlation between NT-proBNP and circadian blood pressure profile in patients with arterial hypertension and chronic heart failure with preserved ejection fraction of the left ventricle

Brain natriuretic peptide levels and renal function in the diagnosis of heart failure in the elderly

Speaker: Doctor M. Escande (Marseille, FR)

Access the full session

Poster Session 4 - Biomarkers

Speakers: Doctor M. Barrett, Doctor M. Dimova-Mileva, Professor V. Maslovskyi, Doctor C. Watson, Doctor M. Escande

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources